ATP Citrate Lyase
ACLYgeneATP citrate lyase controls macrophage acetyl-CoA pools and lipid biosynthesis, influencing the pro-inflammatory versus stabilizing macrophage phenotype in atherosclerotic plaques.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleACLY regulates macrophage lipid metabolism and acetyl-CoA availability; affects plaque inflammatory state and stabilization.
Also acts inLipid entry/oxidation
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000131473
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I23
C — confounder / Type-II59
A — assay feasibility52
E — evidence strength22
T1DI (composite)4
Specificity differential (R−C)-35.2
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable
Literature evidence(1)
- Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques.Nature communications · 2020 · PMID 33293558 · doi